Activation of NF-κB via endosomal toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation

Journal of Virology

Volumn 88, Issue 17, 2014, Pages 10002-10012

  Haas, Florian ^a   Yamauchi, Kazuma ^a,b   Murat, Monika ^a   Bernasconi, Michele ^a   Yamanaka, Noboru ^b   Speck, Roberto F ^c   Nadal, David ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL; C57BL MOUSE; HERPES VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; RHADINOVIRUS; VIROLOGY; VIRUS ACTIVATION; VIRUS INFECTION; VIRUS LATENCY;

ANIMALS; HERPESVIRIDAE INFECTIONS; MEMBRANE GLYCOPROTEINS; MICE, INBRED C57BL; NF-KAPPA B; RHADINOVIRUS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TUMOR VIRUS INFECTIONS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84920082659     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01486-14     Document Type: Article

References (49)

1. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768. http://dx.doi.org/10.1038/nrc1452.
2. Burkitt D. 1962. A children's cancer dependent on climatic factors. Nature 194:232-234. http://dx.doi.org/10.1038/194232a0.
3. Burkitt DP. 1969. Etiology of Burkitt's lymphoma-an alternative hypothesis to a vectored virus. J. Natl. Cancer Inst. 42:19-28.
4. Speck SH, Ganem D. 2010. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 8:100-115. http://dx.doi.org/10.1016/j.chom.2010.06.014.
5. Rickinson AB, Moss DJ. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431. http://dx.doi.org/10.1146/annurev.immunol.15.1.405.
6. Gargano LM, Forrest JC, Speck SH. 2009. Signaling through Toll-like receptors induces murine gammaherpesvirus 68 reactivation in vivo. J. Virol. 83:1474-1482. http://dx.doi.org/10.1128/JVI.01717-08.
7. Gregory SM, West JA, Dillon PJ, Hilscher C, Dittmer DP, Damania B. 2009. Toll-like receptor signaling controls reactivation of KSHV from latency. Proc. Natl. Acad. Sci. U. S. A. 106:11725-11730. http://dx.doi.org/10.1073/pnas.0905316106.
8. Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M, Niggli FK, Speck RF, Nadal D. 2007. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell. Microbiol. 9:2055-2069. http://dx.doi.org/10.1111/j.1462-5822.2007.00937.x.
9. Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D. 2010. TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene 29:4588-4598. http://dx.doi.org/10.1038/onc.2010.203.
10. Takeda K, Akira S. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17:1-14. http://dx.doi.org/10.1093/intimm/dxh186.
11. Pichyangkul S, Yongvanitchit K, Kum-Arb U, Hemmi H, Akira S, Krieg AM, Heppner DG, Stewart VA, Hasegawa H, Looareesuwan S, Shanks GD, Miller RS. 2004. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J. Immunol. 172:4926-4933. http://dx.doi.org/10.4049/jimmunol.172.8.4926.
12. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, Kumar N, Horii T, Akira S. 2005. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201:19-25. http://dx.doi.org/10.1084/jem.20041836.
13. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373-384. http://dx.doi.org/10.1038/ni.1863.
14. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3:499. http://dx.doi.org/10.1038/ni0602-499.
15. Demaria O, Pagni PP, Traub S, de Gassart A, Branzk N, Murphy AJ, Valenzuela DM, Yancopoulos GD, Flavell RA, Alexopoulou L. 2010. TLR8 deficiency leads to autoimmunity in mice. J. Clin. Invest. 120:3651-3662. http://dx.doi.org/10.1172/JCI42081.
16. McGettrick AF, O'Neill LA. 2004. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol. Immunol. 41: 577-582. http://dx.doi.org/10.1016/j.molimm.2004.04.006.
17. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, Akira S. 2002. Cutting edge: a novel Toll/IL-1 receptor domaincontaining adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169:6668-6672. http://dx.doi.org/10.4049/jimmunol.169.12.6668.
18. Bonizzi G, Karin M. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280-288. http://dx.doi.org/10.1016/j.it.2004.03.008.
19. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. 2003. NF-B inhibits gammaherpesvirus lytic replication. J. Virol. 77:8532-8540. http://dx.doi.org/10.1128/JVI.77.15.8532-8540.2003.
20. Izumiya Y, Izumiya C, Hsia D, Ellison TJ, Luciw PA, Kung HJ. 2009. NF-kappaB serves as a cellular sensor of Kaposi's sarcoma-associated herpesvirus latency and negatively regulates K-Rta by antagonizing the RBPJkappa coactivator. J. Virol. 83:4435-4446. http://dx.doi.org/10.1128/JVI.01999-08.
21. Krug LT, Moser JM, Dickerson SM, Speck SH. 2007. Inhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency. PLoS Pathog. 3:e11. http://dx.doi.org/10.1371/journal.ppat.0030011.
22. Virgin HW, IV, Latreille P, Wamsley P, Hallsworth K, Weck KE, Dal Canto AJ, Speck SH. 1997. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71:5894-5904.
23. Clarke GD, Stoker MG, Ludlow A, Thornton M. 1970. Requirement of serum for DNA synthesis in BHK 21 cells: effects of density, suspension and virus transformation. Nature 227:798-801. http://dx.doi.org/10.1038/227798a0.
24. Efstathiou S, Ho YM, Minson AC. 1990. Cloning and molecular characterization of the murine herpesvirus 68 genome. J. Gen. Virol. 71(Pt 6):1355-1364. http://dx.doi.org/10.1099/0022-1317-71-6-1355.
25. Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA. 1992. Virological and pathological features of mice infected with murine gamma-herpesvirus 68. J. Gen. Virol. 73(Pt 9):2347-2356. http://dx.doi.org/10.1099/0022-1317-73-9-2347.
26. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T, Akira S, Reis e Sousa C. 2003. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha + DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33:827-833. http://dx.doi.org/10.1002/eji.200323797.
27. Allen RD, III, Dickerson S, Speck SH. 2006. Identification of spliced gammaherpesvirus 68 LANA and v-cyclin transcripts and analysis of their expression in vivo during latent infection. J. Virol. 80:2055-2062. http://dx.doi.org/10.1128/JVI.80.4.2055-2062.2006.
28. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF. 2009. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113:377-388. http://dx.doi.org/10.1182/blood-2008-04-151712.
29. Tibbetts SA, McClellan JS, Gangappa S, Speck SH, Virgin HW, IV. 2003. Effective vaccination against long-term gammaherpesvirus latency. J. Virol. 77:2522-2529. http://dx.doi.org/10.1128/JVI.77.4.2522-2529.2003.
30. Usherwood EJ, Stewart JP, Nash AA. 1996. Characterization of tumor cell lines derived from murine gammaherpesvirus-68-infected mice. J. Virol. 70:6516-6518.
31. Wu TT, Usherwood EJ, Stewart JP, Nash AA, Sun R. 2000. Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency. J. Virol. 74:3659-3667. http://dx.doi.org/10.1128/JVI.74.8.3659-3667.2000.
32. Martinez-Guzman D, Rickabaugh T, Wu TT, Brown H, Cole S, Song MJ, Tong L, Sun R. 2003. Transcription program of murine gammaherpesvirus 68. J. Virol. 77:10488-10503. http://dx.doi.org/10.1128/JVI.77.19.10488-10503.2003.
33. Grossmann C, Ganem D. 2008. Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology 375:94-102. http://dx.doi.org/10.1016/j.virol.2007.12.044.
34. Weck KE, Barkon ML, Yoo LI, Speck SH, Virgin HW, IV. 1996. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. J. Virol. 70:6775-6780.
35. Guggemoos S, Hangel D, Hamm S, Heit A, Bauer S, Adler H. 2008. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J. Immunol. 180:438-443. http://dx.doi.org/10.4049/jimmunol.180.1.438.
36. Forrest JC, Speck SH. 2008. Establishment of B-cell lines latently infected with reactivation-competent murine gammaherpesvirus 68 provides evidence for viral alteration of a DNA damage-signaling cascade. J. Virol. 82:7688-7699. http://dx.doi.org/10.1128/JVI.02689-07.
37. Gururajan M, Jacob J, Pulendran B. 2007. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One 2:e863. http://dx.doi.org/10.1371/journal.pone.0000863.
38. Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A. 2010. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J. Virol. 84:3612-3623. http://dx.doi.org/10.1128/JVI.01400-09.
39. Karin M, Lin A. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:221-227. http://dx.doi.org/10.1038/ni0302-221.
40. Rasmussen SB, Jensen SB, Nielsen C, Quartin E, Kato H, Chen ZJ, Silverman RH, Akira S, Paludan SR. 2009. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible genelike receptors, which synergize to induce type I interferon production. J. Gen. Virol. 90:74-78. http://dx.doi.org/10.1099/vir.0.005389-0.
41. Sato A, Linehan MM, Iwasaki A. 2006. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 103:17343-17348. http://dx.doi.org/10.1073/pnas.0605102103.
42. Fiola S, Gosselin D, Takada K, Gosselin J. 2010. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J. Immunol. 185:3620-3631. http://dx.doi.org/10.4049/jimmunol.0903736.
43. West JA, Gregory SM, Damania B. 2012. Toll-like receptor sensing of human herpesvirus infection. Front. Cell. Infect. Microbiol. 2:122. http://dx.doi.org/10.3389/fcimb.2012.00122.
44. Santoro MG, Rossi A, Amici C. 2003. NF-kappaB and virus infection: who controls whom. EMBO J. 22:2552-2560. http://dx.doi.org/10.1093/emboj/cdg267.
45. Keller SA, Schattner EJ, Cesarman E. 2000. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96:2537-2542.
46. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. 2000. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl. Acad. Sci. U. S. A. 97:6055-6060. http://dx.doi.org/10.1073/pnas.100119497.
47. Gargano LM, Moser JM, Speck SH. 2008. Role for MyD88 signaling in murine gammaherpesvirus 68 latency. J. Virol. 82:3853-3863. http://dx.doi.org/10.1128/JVI.02577-07.
48. Sugano N, Chen W, Roberts ML, Cooper NR. 1997. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J. Exp. Med. 186:731-737. http://dx.doi.org/10.1084/jem.186.5.731.
49. Sadagopan S, Sharma-Walia N, Veettil MV, Raghu H, Sivakumar R, Bottero V, Chandran B. 2007. Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J. Virol. 81:3949-3968. http://dx.doi.org/10.1128/JVI.02333-06.